Treatment of viral myocarditis caused by coxsackievirus B

American Journal of Health-System Pharmacy

Volumn 65, Issue 2, 2008, Pages 132-137

  Brunetti, Luigi ^a   Hermes DeSantis, Evelyn R ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Antivirals; Arsidia chinesis; Astragalas membranaceus; Coxsackievirus infections; Globulin immune; Immunosuppressive agents; Mechanism of action; Myocarditis; Plants; Serums; Site of action

Indexed keywords

ACICLOVIR; ALDOSTERONE ANTAGONIST; ALPHA2A INTERFERON; ANTIBODY; ANTIVIRUS AGENT; ARDISIA CHINENSIS EXTRACT; ASTRAGALOSIDE IV; ASTRAGALUS MEMBRANECEUS EXTRACT; AZATHIOPRINE; BETA INTERFERON; CIDOFOVIR; CYCLOSPORIN; CYTOKINE; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; PLACEBO; PLANT EXTRACT; PLECONARIL; PREDNISONE; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ARDISIA CHINENSIS; ASTRAGALUS MEMBRANACEUS; AUTOIMMUNE DISEASE; CELL DESTRUCTION; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; COXSACKIE VIRUS B; COXSACKIE VIRUS INFECTION; CYTOKINE RELEASE; CYTOTOXICITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EARLY INTERVENTION; HEART FAILURE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; MEDICINAL PLANT; MUSCLE CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SERUM; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; VIRUS MYOCARDITIS;

EID: 38349072003     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060586     Document Type: Review

References (40)

1. Parrillo JE. Inflammatory cardiomyopathy (myocarditis): which patients should be treated with anti-inflammatory therapy? Circulation. 2001; 104:4-6.
2. O'Connell JB, Mason JW. Diagnosing and treating active myocarditis. West J Med. 1989; 150:431-5.
3. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandanavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987; 316:1429-35.
4. Kearney MT, Cotton JM, Richardson PJ et al. Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management. Postgrad Med J. 2001; 77:4-10.
5. Hirschman SZ, Hammer GS. Coxsackie virus myopericarditis: a microbiological and clinical review. Am J Cardiol. 1974; 34:224-32.
6. Fujioka S, Kitaura Y. Coxsackie B virus infection in idiopathic dilated cardiomyopathy: clinical and pharmacological implications. BioDrugs. 2001; 15:791-9.
7. Why HJ, Meany BT, Richardson PJ et al. Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation. 1994; 89:2582-9.
8. Shimojo T, Hiroe M, Ishiyama S et al. Nitric oxide induces apoptotic death of cardiomyocytes via a cyclic-GMP-dependent pathway. Exp Cell Res. 1999; 247:38-47.
9. Spotnitz MD, Lesch M. Idiopathic dilated cardiomyopathy as a late complication of healed viral (Coxsackie B virus) myocarditis: historical analysis, review of the literature, and a postulated unifying hypothesis. Prog Cardiovasc Dis. 2006; 49:42-57.
10. Beck MA. Nutritionally induced oxidative stress: effect on viral disease. Am J Clin Nutr. 2000; 71(6, suppl):1676S-1681S.
11. Hjalmarson Å, Fu M, Mobini R. Who are the enemies? Inflammation and autoimmune mechanisms. Eur Heart J Suppl. 2002; 4(suppl G):G27-32.
12. Feldman AM, McNamara D. Myocarditis. N Engl J Med. 2000; 343:1388-95.
13. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation. 1999; 99:1091-100.
14. Mason JW, O'Connell JB, Herskowitz A et al. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med. 1995; 333:269-75.
15. Pocock SJ, Wang D, Pfeffer MA et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006; 27:65-75.
16. McManus BM, Chow LH, Wilson JE et al. Direct myocardial injury by enterovirus: a central role in the evolution of murine myocarditis. Clin Immunol Immunopathol. 1993; 68:159-69.
17. Camargo PR, Snitcowsky R, da Luz PL et al. Favorable effects of immunosuppressive therapy in children with dilated cardiomyopathy and active myocarditis. Pediatr Cardiol. 1995; 16:61-8.
18. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two year follow-up results. Circulation. 2001; 104:39-45.
19. Noutsias M, Pauschinger M, Poller WC et al. Immunomodulatory treatment strategies in inflammatory cardiomyopathy: current status and future perspectives. Expert Rev Cardiovasc Ther. 2004; 2:37-51.
20. Chen H, Liu J, Yang M. Corticosteroids for viral myocarditis. Cochrane Database Syst Rev. 2006; 4:CD004471.
21. Robinson JL, Hartling L, Crumley E et al. A systemic review of intravenous gamma globulin for therapy of acute myocarditis. BMC Cardiovasc Disord. 2005; 5:12.
22. McNamara DM, Holubkov R, Starling RC et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001; 103:2254-9.
23. Robinson J, Hartling L, Vandermeer B et al. Intravenous immunoglobulin for presumed viral myocarditis in children and adults. Cochrane Database Syst Rev. 2005; 1:CD004370.
24. Drucker NA, Colan SD, Lewis AB et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation. 1994; 89:252-7.
25. Heim A, Stille-Seigener M, Pring-Akerblom P et al. Recombinant interferons beta and gamma have a higher antiviral activity than interferon-alpha in coxsackie B3-infected carrier state cultures of human myocardial fibroblasts. J Interferon Cytokine Res. 1996; 16:283-7.
26. Heim A, Grumbach I, Pring-Akerblom P et al. Inhibition of coxsackievirus B3 carrier state infection of cultured human myocardial fibroblasts by ribavirin and human natural interferon α. Antiviral Res. 1997; 34:101-11.
27. Daliento L, Calabrese F, Tona F et al. Successful treatment of enterovirus-induced myocarditis with interferon-α. J Heart Lung Transplant. 2003; 22:214-7.
28. Kuhl U, Pauschinger M, Scwimmbeck PL et al. Interferon-β treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation. 2003; 107:2793-8.
29. Rotbart HA, Webster AD, for the Pleconaril Treatment Registry Group. Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis. 2001; 32:228-35.
30. Pevear DC, Tull TM, Seipel ME et al. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother. 1999; 43:2109-15.
31. Leonard EG. Viral myocarditis. Pediatr Infect Dis J. 2004; 23:665-6.
32. Lenzo JC, Shellam GR, Lawson CM. Ganciclovir and cidofovir treatment of cytomegalovirus-induced myocarditis in mice. Antimicrob Agents Chemother. 2001; 45:1444-9.
33. Baykurt C, Caglar K, Ceviz N et al. Successful treatment of Epstein-Barr virus infection associated with myocarditis. Pediatr Int. 1999; 41:389-91.
34. Rebecca R, McErlean M. Complete heart block in a child with varicella. Am J Emerg Med. 1993; 11:602-5.
35. Faulkner CF, Godbolt AM, DeAmbrosis B et al. Hand, foot and mouth disease in an immunocompromised adult treated with aciclovir. Australas J Dermatol. 2003; 44:203-6.
36. Natural Medicines Comprehensive Database. Astragalus. www.naturaldatabase.com (accessed 2006 Oct 29).
37. Astragalus membranaceus. Monograph. Altern Med Rev. 2003; 8:72-7.
38. Zhang Y, Zhu H, Huang C et al. Astragaloside IV exerts antiviral effects against coxsackievirus B3 by upregulating interferon-γ. J Cardiovasc Pharmacol. 2006; 47:190-5.
39. Yang YZ, Jin PY, Guo Q et al. Effect of Astragalus membranaceus on natural killer cell activity and induction of α- and γ-interferon in patients with Coxsackie B viral myocarditis. Chin Med J. 1990; 103:304-7.
40. Su M, Li Y, Leung KT et al. Antiviral activity and constituent of Ardisia chinensis benth against coxsackie B3 virus. Phytother Res. 2006; 20:634-9.